Serum levels of IL-6 are usually elevated in mCRPC patients and have been shown to play an important role in driving aggressive PCa phenotypes, cancer progression, metastasis, epithelial-mesenchymal transition (EMT), drug resistance, and cancer cell survival by networking with multiple signaling pathways. The gene discussed is IL6; the disease is cancer.